Accenture October 26, 2021
Savings could be passed on to patients to improve affordability and access
NEW YORK; – A new report from Accenture (NYSE: ACN) identifies three steps biopharmaceutical organizations could take to reduce the average cost of discovering and developing a treatment by more than US$1 billion. Furthermore, it could potentially create additional future revenue opportunities of up to US$450 million per treatment.
The report, titled “From Billions to Millions: Faster innovation. Greater R&D productivity” notes that the cost of bringing a successful treatment to market is between US$2.6 billion and $6.7 billion, depending on therapeutic area, treatment modality and disease complexity. However, the combined use of “New Science” (which is a unique combination of the best in science and health technology that address...
Today's Sponsors
Today's Sponsor
Related Articles:
Source link
[ad_2]
source https://earn8online.com/index.php/370907/biopharma-can-reduce-the-cost-of-bringing-a-treatment-to-market-by-more-than-us1-billion-according-to-accenture-report/
No comments:
Post a Comment